PHARMACEUTICAL ADVERTISING BE BANNED

Pharmaceutical advertising be Banned

Pharmaceutical advertising be Banned

Direct To Consumer (DTC) advocating In Pharmaceuticals

Current and Future Market Outlook, Regulatory Landscape and Case Studies report provides key data, information and analysis of the major issues affecting the stakeholders of the DTC advertising market in the US and Europe. It discusses the major alterations that have been discerned after the relaxation of directions over DTC advertising by the FDA in 1997. The report furthermore wrappings the matters exact to the European market as well where labelled DTC advertising is banned. The report presents a comprehensive outlook of some of the best demonstrations of DTC advocating along with the analysis covering causes for such success. The report furthermore presents a comprehensive investigation of some of the failed demonstrations along with the key learning's from the same. It furthermore presents an insight into the government guidelines in the US and Europe for DTC advertisements and their implications on the marketing schemes of the pharmaceutical companies. The report presents a detailed interpretation of some of the major reasons behind recent expansion in the pharmaceutical DTC advertising landscape. At the end, the report feels upon some of the foremost tendencies that are expected to form the future landscape for the DTC market in the US and Europe.

Main Types Of Medicines

There are two main types of medicines for sale in America: those that require a prescription and those that do not. The last mentioned are known as over-the-counter drugs. Over-the-counter drugs are generally relatively safe and are for conditions that do not require a physician's diagnosis. Other medicines have prescription-only status because a physician's assistance is considered necessary for safe and appropriate use. This may be due to the complex nature of the diagnosis or because of the medicine's potential toxicity.

The restriction on advertising in America is linked to this restriction on sales: manufacturers may advertise prescription-only products to health professionals but not to the general public. The physician is considered a “learned intermediary” and is legally responsible both for the prescribing decision and for warning patients about potential risks. An ongoing legal question in the US has been whether DTCA affects the learned intermediary doctrine. In other words, when manufacturers advertise directly to the public, have they transformed the patient-doctor role to the extent that they also become legally responsible to warn consumers directly?

Do the safety concerns that originally led to restrictions on prescription drug advertising remain justified, or are they an anomaly in the 21st century, given our current educational levels, attitudes towards the use of health care services and the doctor-patient relationship, and access to a broad range of communication media?

Direct-to-consumer advertising of prescription drugs is highly controversial, with many competing claims made about potential benefits and harms. Merck's global departure of the arthritis pharmaceutical rofecoxib (Vioxx) in September 2004 has provoked much newspapers discussion of the effects of DTCA on public safety. Merck had expended more than US $500 million advocating Vioxx to the US public in its five ...